| Literature DB >> 29061194 |
Larry W Chang1,2,3,4, Ismail Mbabali5, Xiangrong Kong6,5, Heidi Hutton7, K Rivet Amico8, Caitlin E Kennedy9,5, Fred Nalugoda5, David Serwadda5, Robert C Bollinger10, Thomas C Quinn10,11, Steven J Reynolds10,5,11, Ronald Gray6,5, Maria Wawer6,5, Gertrude Nakigozi5.
Abstract
BACKGROUND: Effective yet practical strategies are needed to increase engagement in HIV treatment and prevention services, particularly in high-HIV-prevalence hotspots. We designed a community-based intervention called "Health Scouts" to promote uptake and adherence to HIV services in a highly HIV-prevalent fishing community in Rakai, Uganda. Using a situated Information, Motivation, and Behavioral skills theory framework, the intervention consists of community health workers, called Health Scouts, who use motivational interviewing strategies and mobile health tools to promote engagement in HIV treatment and prevention services. METHODS/Entities:
Keywords: Adherence; Antiretroviral therapy; Community health workers; HIV; Male circumcision; Motivational interviewing; Randomized controlled trial; Uganda; mHealth
Mesh:
Substances:
Year: 2017 PMID: 29061194 PMCID: PMC5654192 DOI: 10.1186/s13063-017-2243-6
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Fig. 1The mHealth Lakefolk Actively Keeping Engaged (mLAKE) study flow diagram
Fig. 2mHealth Lakefolk Actively Keeping Engaged (mLAKE) trial cluster map (intervention: clear, control; grayed)
PRECIS-2 scores for the mHealth Lakefolk Actively Keeping Engaged (mLAKE) trial
| Domains | Scorea | Rationale |
|---|---|---|
| Eligibility | 5 | All residents ≥ 15 years of age are eligible for study participation, identical to usual care |
| Recruitment | 4 | Recruitment effort (community sensitization, drama shows, and Health Scouts approaching residents) is likely modestly above what would be expected in usual care |
| Setting | 4 | The setting is mostly similar in key characteristics (e.g., high-risk population) to other usual-care settings |
| Organization | 3 | The care delivery organization is likely much higher resourced than most usual-care organizations but efforts were made to replicate more usual-care resource capacity |
| Flexibility (delivery) | 5 | Flexibility is anticipated to be the same in how the intervention is delivered in the trial and flexibility anticipated in usual care |
| Flexibility (adherence) | 5 | No special trial measures to promote participant participation with Health Scout intervention |
| Follow-up | 3 | Participants being surveyed every at regular intervals in this trial which may be different from other settings |
| Primary outcome | 5 | Outcome is very directly relevant to participants |
| Primary analyses | 5 | All data will be included in the analysis of the primary outcomes |
aPRECIS 5-point Likert Scale, 1 = very explanatory, 2 = rather explanatory, 3 = equally pragmatic/explanatory, 4 = rather pragmatic, 5 = very pragmatic
Fig. 3PRECIS-2 wheel for the mHealth Lakefolk Actively Keeping Engaged (mLAKE) trial
Fig. 4Health Scout intervention conceptual framework
Fig. 5Example screenshots from Health Scout smartphone application
Health Scout mHealth application counseling modules
| # | Module description |
|---|---|
| 1 | HIV serostatus unknown or no recent HIV test, male or not pregnant female |
| 2 | HIV serostatus unknown or no recent HIV test, pregnant female |
| 3 | Male, not circumcised |
| 4 | HIV+, not in care |
| 5 | HIV+, in care, not on antiretroviral therapy (ART) |
| 6 | HIV+, on ART |
| 7 | HIV+, pregnant |
| 8 | Male having condomless sex |
| 9 | Female having condomless sex |
Fig. 6Example of counseling module flow and content: HIV-positive, not yet in care
Descriptions of mHealth Lakefolk Actively Keeping Engaged (mLAKE) trial primary (1°) and secondary (2°) study outcomesa
| Outcome | Description | Numerator/event | Denominator | |
|---|---|---|---|---|
| 1° | HIV care coverageb | Proportion | # linked to HIV care | # HIV-positive |
| 1° | ART coverageb | Proportion | # on antiretroviral therapy (ART) | # HIV-positive |
| 1° | MC coverageb | Proportion | # non-Muslim men circumcised | All non-Muslim men aged 15–49 years |
| 1° | HIV population viremia prevalence (PVP) | Proportion | HIV+ c VL > 400 | All study participants |
| 2° | HIV incidence | Rate | # new HIV infections | HIV-negative person-years |
| 2° | HTS coverage | Proportion | # ever tested and received HIV results | All study participants |
| 2° | ART treatment failurec | Proportion | Composite: virologic failure | # initiated on ART |
| 2° | Consistent condom useb | Proportion | # using condoms consistently past 12 months | # sexually active |
aOutcomes described at the cluster level; outcomes may also be analyzed at the individual level
bSelf-reported
cOutcomes will also be individually analyzed. Virologic failure = any viral load (VL) > 1000 copies/mL. Lost to follow-up = no clinic visit > 180 days
ART antiretroviral therapy, HTS HIV Testing Services, MC male circumcision
Power calculation parameters and derivation of control arm outcome estimates at the end of the trial
| Characteristics | CV | ICC | 2013 | 2015 | 2013 to 2015 ∆ | Proposed control arm outcome |
|---|---|---|---|---|---|---|
| Population viremia prevalence (PVP) | 0.33 | 0.02 | 25% | 16% | 9% | 11.2% |
| HIV care coverage | 0.141 | 0.061 | 70% | 75% | 4.8% | 80.1% |
| ART coverage | 0.187 | 0.072 | 43% | 67% | 24.6% | 79.7% |
| MC coverage | 0.209 | 0.062 | 52% | 59% | 8.1% | 66.9% |
| HIV incidence | 0.929 | NA | 3.34 | 2.9 | 0.44 | 2.7 |
ART antiretroviral therapy, MC male circumcision, NA not applicable
Calculation of minimum detectable difference (MDD) for the mHealth Lakefolk Actively Keeping Engaged (mLAKE) trial
| Outcome | Control proportion | % Contamination | Control proportion + contamination | Intervention proportion | MDD ratio | MDD difference |
|---|---|---|---|---|---|---|
| PVP | 0.112 | 0 | 0.112 | 0.066 | 0.593 | −0.046 |
| PVP | 0.112 | 0.1 | 0.107 | 0.063 | 0.559 | −0.049 |
| PVP | 0.112 | 0.2 | 0.101 | 0.059 | 0.524 | −0.053 |
| PVP | 0.112 | 0.3 | 0.095 | 0.054 | 0.482 | −0.058 |
| PVP | 0.112 | 0.4 | 0.087 | 0.048 | 0.433 | −0.064 |
| PVP | 0.112 | 0.5 | 0.077 | 0.041 | 0.37 | −0.071 |
| HIV care coverage | 0.801 | 0 | 0.801 | 0.92 | 1.149 | 0.119 |
| HIV care coverage | 0.801 | 0.1 | 0.814 | 0.934 | 1.147 | 0.12 |
| HIV care coverage | 0.801 | 0.2 | 0.831 | 0.952 | 1.145 | 0.121 |
| HIV care coverage | 0.801 | 0.3 | 0.854 | 0.976 | 1.144 | 0.122 |
| HIV care coverage | 0.801 | 0.4 | NA | NA | NA | NA |
| HIV care coverage | 0.801 | 0.5 | NA | NA | NA | NA |
| ART coverage | 0.797 | 0 | 0.797 | 0.952 | 1.195 | 0.155 |
| ART coverage | 0.797 | 0.1 | 0.814 | 0.971 | 1.193 | 0.157 |
| ART coverage | 0.797 | 0.2 | 0.837 | 0.997 | 1.191 | 0.16 |
| ART coverage | 0.797 | 0.3 | NA | NA | NA | NA |
| ART coverage | 0.797 | 0.4 | NA | NA | NA | NA |
| ART coverage | 0.797 | 0.5 | NA | NA | NA | NA |
| MC coverage | 0.669 | 0 | 0.669 | 0.822 | 1.229 | 0.153 |
| MC coverage | 0.669 | 0.1 | 0.686 | 0.842 | 1.227 | 0.156 |
| MC coverage | 0.669 | 0.2 | 0.709 | 0.869 | 1.225 | 0.16 |
| MC coverage | 0.669 | 0.3 | 0.739 | 0.904 | 1.222 | 0.164 |
| MC coverage | 0.669 | 0.4 | 0.783 | 0.955 | 1.219 | 0.172 |
| MC coverage | 0.669 | 0.5 | NA | NA | NA | NA |
| HIV incidence | 0.027 | 0 | 0.027 | 0.005 | 0.201 | −0.021 |
| HIV incidence | 0.027 | 0.1 | 0.025 | 0.005 | 0.176 | −0.022 |
| HIV incidence | 0.027 | 0.2 | 0.022 | 0.004 | 0.146 | −0.023 |
| HIV incidence | 0.027 | 0.3 | 0.02 | 0.003 | 0.116 | −0.024 |
| HIV incidence | 0.027 | 0.4 | 0.017 | 0.002 | 0.08 | −0.025 |
| HIV incidence | 0.027 | 0.5 | 0.014 | 0.001 | 0.05 | −0.025 |
ART antiretroviral therapy, MC male circumcision, NA not applicable, PVP population viremia prevalence
Fig. 7SPIRIT Figure; the mHealth Lakefolk Actively Keeping Engaged (mLAKE) trial schedule of enrollment, interventions, and assessments